Background
Chronic pain is treated with NSAIDs or opioids that reduce nociceptive signaling. While these drugs relieve discomfort, they also inhibit enzymes that modulate mitochondrial reactive oxygen species (ROS) production, such as cyclooxygenase‑2 (COX‑2) and microsomal prostaglandin E synthase‑1 (mPGES‑1)[https://www.medcentral.com/meds/pain/do-nsaids-cause-more-deaths-opioids]. Low‑level ROS act as mitohormetic signals that activate Nrf2, FOXO, and autophagy pathways, promoting stress resistance and longevity[https://doi.org/10.1101/2023.10.24.563703]. ’s analysis shows excess mortality from analgesics stems from organ toxicity, not loss of a nociceptive longevity cue, but does not address whether analgesic‑induced ROS suppression interferes with mitohormesis.
Mechanistic proposal
We hypothesize that sustained analgesic exposure diminishes basal mitochondrial ROS flux below the threshold needed to trigger mitohormetic adaptation. This creates a "ROS silence" that:
- Reduces Nrf2 nuclear translocation, lowering expression of antioxidant genes (HO‑1, SOD2) and diminishing cellular capacity to handle oxidative stress.
- Decreases PGC‑1α‑driven mitochondrial biogenesis, leading to a modest but chronic decline in oxidative phosphorylation efficiency.
- Attenuates autophagosome formation via reduced AMPK activation, allowing accumulation of damaged mitochondria and promoting senescence‑associated secretory phenotype (SASP). Together, these effects accelerate inflammaging independently of the drugs’ direct toxicities.
Testable predictions
- Prediction 1: In





























